To benchmark the utility of E06: A half-life extension, single-domain, shark antibody bio-tool, and progress it to a Phase 1 ready candidate clone

从科学上讲，我们正在开发一种“生物工具”，它可以与一系列不同的治疗蛋白/多肽融合，将它们的血清半衰期从几个小时延长到几周，并有可能极大地提高它们的治疗效力。它的工作原理是搭乘血液中其他长寿蛋白质的便车。在商业上，我们的中期目标是在我们独特的单域鲨鱼抗体(VNAR)平台的基础上创建一家药物发现公司，该平台将在内部或与较大公司合作开发治疗剂。要实现这一点，满足科学里程碑是关键，特别是确认非免疫原性(人类免疫系统看不到，使用安全)，并验证我们最先进的产品(E06 VNAR半寿命延长生物工具)。实现这一目标的进展还将为新公司的成立和股权融资提供一个平台，并将交付一项能够确保许可和合作收入的多种收入来源的资产。

Scientifically we are developing a "bio-tool" that could be fused to a range of different therapeutic proteins/peptides to extend their serum half-life from hours to weeks, with the potential of greatly increasing their therapeutic potency. It works by hitching a ride on other long-lived proteins in the blood. Commercially, our medium-term goal is to create a Drug Discovery company, based on our unique, single-domain shark antibody (VNAR) platform, which will develop therapeutic agents in-house or in partnership with larger companies. To achieve this, meeting of scientific milestones is key, and in particular confirming non-immunogenicity (not seen by the human immune system & safe for use), and validate the most advanced of our products (E06 VNAR half-life extension bio-tool). Progress towards this goal will also provide a platform for NewCo formation and equity raising, and will deliver an asset capable of securing multiple revenue streams of licensing and partnered income.